DSIP 2500 mcg
DSIP, or delta sleep inducing peptide, is a synthetic nonapeptide primarily researched for its effects on sleep regulation, stress response, and neuroendocrine modulation. It is commonly discussed in recovery and restorative settings where sleep quality, stress resilience, and nervous system balance are prioritised. DSIP is valued for its regulatory and restorative profile rather than anabolic, hormonal replacement, or physique driven outcomes, although its biological role remains incompletely understood in the literature.
DSIP, or delta sleep inducing peptide, is a synthetic nonapeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. It was originally reported as a sleep related peptide after early animal and human work, but later reviews made its natural origin and precise biological role much less certain. Because of that, DSIP is best described as an investigational regulatory peptide studied for sleep, stress, and neuroendocrine effects rather than a definitively characterised endogenous hormone or clinically established therapy.
Properties and Effects
May support sleep onset and sleep quality in some research settings.
May support stress resilience and adaptive responses.
May influence pain perception and recovery related comfort.
May affect neuroendocrine signalling, including corticotropin and growth related pathways.
Does not act as an anabolic steroid, testosterone analogue, or SERM.
Mechanism of Action
DSIP does not have one well established modern mechanism of action. The literature instead describes it as a multifunctional regulatory peptide with effects on sleep related activity, stress adaptation, autonomic regulation, and endocrine signalling. Published work has linked DSIP to changes in hypothalamic pituitary pathways, adrenergic responses, and broader neurochemical regulation, but the overall mechanism remains unresolved and controversial.
Recommended Use
DSIP is typically discussed in sleep support, recovery, and stress management protocols. The older human literature focused mainly on disturbed sleep and insomnia related settings, while later reviews expanded interest into stress protection and neuroregulation. It is more accurate to frame DSIP as a restorative or regulatory research compound than as a mainstream performance enhancer or body composition product.
Safety and Side Effects
Human data is limited and mostly older. The literature suggests that DSIP was generally tolerated in the small insomnia studies, but the evidence base is thin by modern clinical standards and some physiological effects have been paradoxical across different experiments. It would therefore be inaccurate to present DSIP as a fully settled or well validated clinical sleep therapy.
Special Notes
DSIP is not a steroid, growth hormone, SARM, or SERM. It is best classified as an investigational neuroregulatory peptide. A key caution for thesis writing is that the literature itself remains uncertain about what DSIP fundamentally is and how much of its reported activity reflects a true endogenous peptide versus DSIP like activity, so claims about it should be made conservatively.
Recommended dosage
There is no universally accepted modern dosing standard. In older human sleep studies, DSIP was commonly studied at 25 nmol/kg intravenously, which is roughly 21 mcg/kg based on the peptide molecular weight, or about 1.5 mg for a 70 kg adult. For a DSIP 2500 mcg vial, that means the total amount is roughly in the range of one to two literature scale administrations, depending on body weight and protocol.
Timing of doses
The older sleep literature generally placed DSIP before the intended sleep period rather than earlier in the day. Some studies used administration before sleep, while others explored morning dosing and still reported later nocturnal effects. For thesis purposes, the safest wording is that DSIP timing in the literature is protocol dependent, though sleep focused use is most often described around the evening or pre sleep window.
Practical guidance
DSIP should be treated as a low certainty research compound rather than a well standardised clinical agent. The older literature suggests that administration protocol matters, but the evidence is too inconsistent to justify precise modern style optimisation claims. Conservative interpretation, careful documentation, and realistic expectations are more defensible than aggressive dosing or strong performance based claims.
Estimated Degradation
Model classification
Moderate stability in lyophilised form, but limited stability once reconstituted into aqueous solution. Available handling guidance from peptide suppliers consistently treats reconstituted DSIP as short lived relative to the dry powder form.
Evidence strength
Moderate for general peptide handling and storage reasoning, weak for exact real world post reconstitution potency in a user handled vial. I did not find a validated published week by week assay curve for a reconstituted DSIP vial under consumer style storage conditions.
Assumption used
Reconstituted with bacteriostatic water and stored refrigerated at 2 to 8 degrees Celsius, protected from light, with minimal agitation and no repeated freeze thaw cycles. Supplier style guidance commonly recommends using reconstituted DSIP within about 5 to 7 days at 4 degrees Celsius, which supports a conservative degradation model for longer storage.
Estimated degradation model for DSIP 2500 mcg
| Time after mixing | Estimated remaining potency | Estimated degradation |
|---|---|---|
| 1 week | 94% | 6% |
| 2 weeks | 87% | 13% |
| 3 weeks | 79% | 21% |
| 4 weeks | 70% | 30% |
| 5 weeks | 60% | 40% |
| 6 weeks | 50% | 50% |
Additional Product Information
| Product Name | DSIP 2500 mcg |
|---|---|
| Also Known As | Delta Sleep Inducing Peptide |
| Product Stock Code | VM-DSIP-2500-1 |
| Categories |  Peptides / Growth Hormones |
| Contents | Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. |
| Presentation Size | 2500 mg per vial |
| Strength | 2500 mcg per box |
| Product Container | Peptides |
More Information
Please login to view more
